【摘要】 目的观察卡培他滨联合奥沙利铂治疗晚期胃癌的疗效和毒性反应。方法将50例晚期胃癌患者随机分为A组和B组,每组各25例。A组:卡培他滨1 000 mg/m2,每天2次口服,d1～14;奥沙利铂130 mg/m2,静脉滴注2 h,d1。B组:亚叶酸钙200 mg/d,静脉滴注2 h,d1～5;5-Fu 750 mg/d,缓慢静脉滴注2 h,d1～5;奥沙利铂130 mg/m2,静脉滴注2 h,d1。上述疗法3周为1个周期。结果两组疗效比较,差异无统计学意义(P>0.05),A组消化系统毒性反应明显低于B组(P<0.01)。结论卡培他滨联合奥沙利铂治疗晚期胃癌可在临床上推广应用。更多还原

【Abstract】 Objective To observe the efficacy and toxicity of the chemotherapy of Capecitabine combined with Oxaliplatin in treatment of patients with advanced gastric cancer.Methods 50 patients with advanced gastric cancer were randomly divided into group A and group B,with 25 cases respectively.Group A: Capecitabine 1 000 mg/m2,po,bid,d1-14;Oxaliplatin 130 mg/m2,ivgtt(2 h),d1;Group B: Leucovorin 200 mg/d,ivgtt(2 h),d1~5;Fluorouracil 750 mg/d,ivgtt(8 h),d1-5;Oxaliplatin 130 mg/m2,ivgtt(2 h),d1.They were repeated every 3 weeks.Results The differences in clinical efficacy were not obvious between the two groups(P > 0.05).The toxicity of digestive systemtoxicity in group A was obviously milder than the toxicity in group B(P < 0.01).Conclusion The chemotherapy of Capecitabine combined with Oxaliplatin is worthwhile to be applied widely in treatment of patients with advanced gastric cancer.更多还原